BiologicsMD™ is a Preclinical Therapeutic Company Focused on Developing Highly-Targeted Parathyroid Hormone Receptor-Mediated Treatments for Hair Loss, Bone Disorders and Oncology.

BiologicsMD is developing a series of patent-protected recombinant fusion proteins, each with two functional domains. The first, the Active Domain, provides powerful stimulatory effects at the target receptors and the second, the Binding Domain, localizes the treatment to the point of disease for sustained, targeted, therapeutic exposure with a single, or infrequent,
dosing and minimal off-target effects.

First-in-Class Hair Cycle Stimulators for the Treatment of Alopecia
of Various Causes

 

BiologicsMD has three programs focused on restoring hair growth and preventing hair loss by stimulating receptors at the hair follicle in conditions of alopecia areata, androgenetic alopecia, and
chemotherapy-induced alopecia.

These compounds are fusion proteins with an Active Domain (parathyroid hormone agonist) coupled to a Binding Domain that targets type I collagen. The Active Domain is designed to stimulate the hair follicles and restore hair growth while the Binding Domain targets and retains the treatment in the skin for a localized and sustained response with limited off-target effects. This novel mechanism of action has been shown to promote hair growth more effectively and without the serious side effects of existing treatments in animal models of alopecia, and does so with dosing as infrequent as once every 1 to 6 months.

 

Targeted Modulators of Bone Growth

 

BiologicsMD has three programs focused on bone disorders including a new bone graft substitute for use in spinal fusion, a bone growth stimulator for post-menopausal osteoporosis, and compounds for the prevention and treatment of bone metastases in metastatic breast and prostate cancer. These treatments utilize the Company’s proprietary fusion protein technology with a Binding Domain to target and retain the treatments in the bone for a localized and sustained effect, and an Active Domain to achieve a
therapeutic response.